Cargando…
Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
Type 2 diabetes affects more than 350 million people worldwide, and its prevalence is increasing. Many patients with diabetes do not achieve and/or maintain glycemic targets, despite therapy implementation and escalation. Multiple therapeutic classes of agents are available for the treatment of type...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003262/ https://www.ncbi.nlm.nih.gov/pubmed/24790417 http://dx.doi.org/10.2147/PPA.S59169 |
_version_ | 1782313830601195520 |
---|---|
author | Salvo, Marissa C Brooks, Amie D Thacker, Stacey M |
author_facet | Salvo, Marissa C Brooks, Amie D Thacker, Stacey M |
author_sort | Salvo, Marissa C |
collection | PubMed |
description | Type 2 diabetes affects more than 350 million people worldwide, and its prevalence is increasing. Many patients with diabetes do not achieve and/or maintain glycemic targets, despite therapy implementation and escalation. Multiple therapeutic classes of agents are available for the treatment of type 2 diabetes, and the armamentarium has expanded significantly in the past decade. Selective sodium glucose co-transporter 2 inhibitors, including dapagliflozin, represent the latest development in pharmacologic treatment options for type 2 diabetes. This class has a unique mechanism of action, working by increasing glucose excretion in the urine. The insulin-independent mechanism results in decreased serum glucose, without hypoglycemia or weight gain. Dapagliflozin is a once-daily oral therapy. Expanding therapy options for a complex patient population is critical, and dapagliflozin has a distinct niche that can be a viable option for select patients with diabetes. |
format | Online Article Text |
id | pubmed-4003262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40032622014-04-30 Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin Salvo, Marissa C Brooks, Amie D Thacker, Stacey M Patient Prefer Adherence Review Type 2 diabetes affects more than 350 million people worldwide, and its prevalence is increasing. Many patients with diabetes do not achieve and/or maintain glycemic targets, despite therapy implementation and escalation. Multiple therapeutic classes of agents are available for the treatment of type 2 diabetes, and the armamentarium has expanded significantly in the past decade. Selective sodium glucose co-transporter 2 inhibitors, including dapagliflozin, represent the latest development in pharmacologic treatment options for type 2 diabetes. This class has a unique mechanism of action, working by increasing glucose excretion in the urine. The insulin-independent mechanism results in decreased serum glucose, without hypoglycemia or weight gain. Dapagliflozin is a once-daily oral therapy. Expanding therapy options for a complex patient population is critical, and dapagliflozin has a distinct niche that can be a viable option for select patients with diabetes. Dove Medical Press 2014-04-22 /pmc/articles/PMC4003262/ /pubmed/24790417 http://dx.doi.org/10.2147/PPA.S59169 Text en © 2014 Salvo et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Salvo, Marissa C Brooks, Amie D Thacker, Stacey M Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
title | Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
title_full | Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
title_fullStr | Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
title_full_unstemmed | Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
title_short | Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
title_sort | patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003262/ https://www.ncbi.nlm.nih.gov/pubmed/24790417 http://dx.doi.org/10.2147/PPA.S59169 |
work_keys_str_mv | AT salvomarissac patientconsiderationsinthemanagementoftype2diabetescriticalappraisalofdapagliflozin AT brooksamied patientconsiderationsinthemanagementoftype2diabetescriticalappraisalofdapagliflozin AT thackerstaceym patientconsiderationsinthemanagementoftype2diabetescriticalappraisalofdapagliflozin |